COMMUNIQUÉS West-GlobeNewswire
-
Nutrition International : Nutrition International and UNFPA partner to improve women and adolescent girls' health
11/07/2017 - 14:00 -
Bavarian Nordic A/S - Articles of Association
11/07/2017 - 13:54 -
uniQure Presents New Clinical Data in Hemophilia B Patients Demonstrating Therapeutic Efficacy of AAV5 Gene Therapy in the Presence of Pre-Existing Neutralizing Antibodies
11/07/2017 - 12:30 -
Össur hf: Q2 2017 Results - Conference call Wednesday 26 July
11/07/2017 - 12:09 -
Vistin Pharma ASA : Vistin Pharma announces the sale of its Opioids and CMO business
11/07/2017 - 12:03 -
Labiaplasty Is the World's Fastest Growing Cosmetic Surgery Procedure, International Study Reports
11/07/2017 - 10:00 -
NEOVACS : Le Comité Indépendant de Surveillance des Données et de la Tolérance confirme le bon déroulement de l'essai clinique de phase IIb dans le lupus
11/07/2017 - 07:30 -
Neovacs Announces Positive IDSMB Review for Phase IIb Clinical Trial of IFNalpha Kinoid in Lupus
11/07/2017 - 07:30 -
Sanofi to acquire Protein Sciences
11/07/2017 - 07:00 -
Sanofi sur le point d'acquérir Protein Sciences
11/07/2017 - 07:00 -
uniQure Announces Updated, Long-Term Clinical Data from Ongoing Phase I/II Trial of AMT-060 In Patients with Severe Hemophilia B
10/07/2017 - 19:01 -
Ossur Hf : Transactions in relation to share buyback program
10/07/2017 - 18:00 -
Sanofi : Disclosure of trading in own shares
10/07/2017 - 18:00 -
Sanofi : Déclaration des transactions sur actions propres
10/07/2017 - 18:00 -
GENFIT : BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITE CONTRACTE AVEC CIC
10/07/2017 - 17:50 -
GENFIT: HALF-YEAR REPORT OF LIQUIDITY CONTRACT WITH CIC
10/07/2017 - 17:50 -
Medtronic Expands TAVR Access to More Patients With Symptomatic, Severe Aortic Stenosis Upon Intermediate Risk FDA Approval
10/07/2017 - 17:35 -
Sanofi Genzyme and Alnylam Report Positive Results from Ongoing phase 2 Open-Label Extension Study with Investigational RNAi Therapeutic Fitusiran in Patients with Hemophilia A and B With or...
10/07/2017 - 15:30 -
Sanofi Genzyme et Alnylam présentent les résultats positifs de l'étude de prolongation de phase 2 en ouvert portant sur le fitusiran, un agent thérapeutique expérimental ARNi, chez des patients...
10/07/2017 - 15:30
Pages